Logo

Opaldia to Distribute Agendia s MammaPrint and CupPrint Tests in UK

Mar 30, 2006

NEW YORK, March 30 (GenomeWeb News) - Opaldia will distribute Agendia's MammaPrint and CupPrint tests in the United Kingdom, the companies said today.

 

MammaPrint uses a 70-gene profile to classify breast cancer patients as 'low' or 'high' risk for developing distant metastasis in a 10-year period.

 

The CupPrint test, meantime, is intended to identify the primary tumor in patients with cancer of unknown primary.

 

Financial terms of the agreement were not disclosed.

Breaking News
The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.